Aerobic Fitness in Multiple Sclerosis: The Relationship Between Balance and Sensory Dual-Tasking
The Effect of Aerobic Fitness on Balance-Related Sensory Dual-Task Performance in Patients With Multiple Sclerosis
The aim of this study is to comparatively examine the effect of aerobic fitness levels on walking and balance performance, sensory dual-task (proprioceptive and vestibular) performance, balance confidence, and fatigue levels in individuals diagnosed with MS.
Research hypotheses H1: MS patients with high aerobic fitness exhibit superior walking speed and balance performance compared to MS patients with low aerobic fitness.
H2: In sensory dual-task tests involving proprioceptive and vestibular manipulations (BOSU ball, soft surface, and head movements synchronized with a metronome), MS patients with high aerobic fitness demonstrate better performance than the group with low aerobic fitness.
H3: MS patients with high aerobic fitness report higher levels of balance confidence compared to the group with low aerobic fitness.
H4: Perceived fatigue is greater in MS patients with low aerobic fitness compared to the group with high aerobic fitness.
H5: There is a significant relationship between aerobic capacity levels and sensory dual-task performance, balance confidence, and fatigue severity in MS patients.
調査の概要
状態
条件
詳細な説明
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Aleyna OZDAMAR YUCEL, MSc
- 電話番号:+90 507 950 74 57
- メール:aleynayucel@sdu.edu.tr
研究連絡先のバックアップ
- 名前:MEHMET DURAY, associate professor
- 電話番号:+90 506 473 11 65
- メール:mehmetduray@sdu.edu.tr
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Having been diagnosed with Relapsing-Remitting or Progressive MS.
- Being between 18-65 years of age.
- Having an Expanded Disability Status Scale score between 1.5-5.
- Being able to walk independently or with a unilateral assistive device.
- Having full cooperation and orientation, and a cognitive level to understand given commands: Mini Mental Test score of 24 or higher.
Exclusion Criteria:
- Having experienced an MS relapse or received acute corticosteroid treatment within the last 3 months.
- Having an additional neurological, orthopedic, or rheumatological condition unrelated to MS that may affect balance and walking.
- Having severe cardiovascular or respiratory disease that may make aerobic fitness assessment risky.
- Having significant vision or hearing loss that would impede understanding test instructions.
- Experiencing significant pain during measurements.
- Having cognitive impairment that would prevent understanding or answering questions - scoring below 24 on the Minimental Test.
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
Those with High Aerobic Fitness: Joint Clinical and Dual Duty Protocol
Data will be collected once using a Personal Information Form, the Timed 25-Step Walk Test (T25WWT), the Timed Up and Walk Test (TUWT), the Berg Balance Scale (BBS), the Modified Clinical Sensory Interaction Test (MCIET), the Activity-Specific Balance Confidence Scale (ASBCS), and the Modified Fatigue Impact Scale (MFIS).
|
|
Individuals with Low Aerobic Fitness: Joint Clinical and Dual Duty Protocol
Data will be collected once using a Personal Information Form, the Timed 25-Step Walk Test (T25WWT), the Timed Up and Walk Test (TUWT), the Berg Balance Scale (BBS), the Modified Clinical Sensory Interaction Test (MCIET), the Activity-Specific Balance Confidence Scale (ASBCS), and the Modified Fatigue Impact Scale (MFIS).
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
6-Minute Walk Test
時間枠:Day 1
|
Participants' aerobic fitness, walking endurance, and functional exercise capacity will be assessed using the 6DKYT.
Participants are asked to walk for 6 minutes at their own determined maximum safe pace in a 30-meter straight corridor, and the total distance covered is recorded in meters.
|
Day 1
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Timed 25-Step Walking Test
時間枠:Day 1
|
To assess participants' baseline walking performance and speed, the Z25AYT, a subtest of the universal Multiple Sclerosis Functional Composite Battery, will be administered.
Participants will be asked to walk a distance of 25 steps (approximately 7.62 meters) as quickly and safely as possible, and the elapsed time will be measured with a stopwatch and recorded in seconds.
|
Day 1
|
|
Dual Task Performance Test: Standing (Static Balance) Tasks
時間枠:Day 1
|
|
Day 1
|
|
Dual Task Performance Test: Walking (Dynamic Balance) Tasks
時間枠:Day 1
|
|
Day 1
|
|
Berg Balance Scale
時間枠:Day 1
|
Participants' objective balance and fall risk will be measured using the BDI (Brain Stability Inventory).
The scale consists of 14 different functional balance tasks, including sitting, standing, reaching, and turning, and is evaluated on a scale of 0-56 points.
Lower scores indicate an increased risk of falls.
|
Day 1
|
|
Activity-Specific Balance Confidence Scale
時間枠:Day 1
|
The 16-item Fall Fear and Balance Confidence Scale (FDSS) will be administered to assess fall fear and balance confidence during daily living activities.
The FDSS consists of 16 items scored between 0 and 100.
Each item asks the individual to rate their confidence in their ability to maintain their balance without falling during a specific activity, on a scale of 0 (not confident at all) to 100 (completely confident).
The total score is calculated by taking the arithmetic mean of all items, resulting in a value between 0 and 100.
A higher total score indicates that the individual has high balance confidence and reduced fall fear during daily living activities.
|
Day 1
|
|
Modified Fatigue Impact Scale
時間枠:Day 1
|
To assess the impact of fatigue on physical, cognitive, and psychosocial functions, a 21-item fatigue risk assessment scale will be used.
The fatigue risk assessment scale consists of 21 items that inquire about fatigue experiences over the past four weeks.
Each item evaluates the impact of fatigue on daily life using a Likert-type scale ranging from 0 (never) to 4 (always).
The total score obtainable from the scale ranges from 0 to 84.
An increase in the total score indicates a greater negative impact of fatigue on the patient's physical, cognitive, and psychosocial functions, and a greater impact on quality of life.
|
Day 1
|
協力者と研究者
捜査官
- スタディディレクター:MELİKE DOĞAN ÜNLÜ, NEUROLOGIST ASSOCIATE PROFESSO、Suleyman Demirel University
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- SüleymanDU-126/9
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。